Capvizr
News · All summaries
Unclassified
Alethio Therapeutics
Series AUndisclosed
RoundSeries A
AmountUndisclosed
HQOxford, United Kingdom
DateNovember 5, 2026
THE DEAL, AT A GLANCE

Alethio Therapeutics

From the announcement
Medicine development
What it doesAlethio Therapeutics is dedicated to developing innovative, disease-modifying therapies for chronic blood cancers.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
What happenedAlethio Therapeutics raised Series A, announced 2026-11-05From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Why it mattersAlethio Therapeutics raised a $90M Series A to advance therapies for myeloproliferative neoplasms, placing the round at the 76th percentile by size among tracked…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Alethio Therapeutics · Financing Record

Explore source-linked visual explanations for Alethio Therapeutics. Unsupported claims are withheld while source review continues.

Record 15378 · Recorded date: 2026-11-05

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime